Navigation Links
ThromboGenics Establishes Level 1 ADR Program for US Investors
Date:9/29/2013

New York, NY 10005

In the U.S.: (866) JPM-ADRS  

Outside the U.S.: (+1 866  576-2377)

Or visit J.P. Morgan Depositary Receipts Services at http://www.adr.com.

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.  

ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA® for a number of new vitreoretinal indications.

In Europe, JETREA® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Alcon has launched JETREA® in the UK, Germany, Denmark, Norway, Finland and Sweden.  

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction.  No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.


'/>"/>
SOURCE ThromboGenics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pittcon Establishes a Collaborative Program Resource Team for 2014
2. Alacrita Establishes U.S. Headquarters in Boston Area
3. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
4. FDA Establishes New Product Codes for Interbody Devices With Integrated Fixation
5. RURO Adds Critical Level Monitoring Functionality to its Transgenic Animal Management Software ezColony
6. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
7. Desktop printing at the nano level
8. Low Blood DHA Levels Linked to Decreased Reading Ability and Memory Performance in Children
9. New Study Reveals that PEEK Polymer Spinal Cage Is Superior to Titanium in Surgical Treatment of Multilevel Cervical Spondylotic Myelopathy
10. Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference
11. IntraMed Diagnostics Announces Two Senior-Level Additions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , June 28, 2017 Spectrecology LLC has ... their STEM education and research dollars. The program is ... latest fiber optic spectroscopy and photonics equipment despite current ... Innovations in Spectroscopy ... of equipment purchases used for the classroom or research. ...
(Date:6/28/2017)... ... 28, 2017 , ... Ovation Fertility continues to ... presentation at the 33rd Annual Meeting of the European Society of Human ... world’s top thought leaders in reproductive medicine – are expected to attend the ...
(Date:6/28/2017)... MO (PRWEB) , ... June 28, 2017 , ... Supplies ... panel of leading experts gathered at the Society of Nuclear Medicine and Molecular Imaging ... isotope of technetium-99m (Tc-99m), which is used in 30 to 40 million nuclear medicine ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... brain mirroring wellness product via Kickstarter campaign on June 15th to fund production ... pre-ordered the B2v2, exceeding the original Kickstarter goal by more than 150% in ...
Breaking Biology Technology:
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... prestigious international IAIR Award for the most innovative high security ePassport and ... ... Maldives Immigration Controller General, Mr. Mohamed ... the right) have received the IAIR award for the "Most innovative high ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
Breaking Biology News(10 mins):